303 related articles for article (PubMed ID: 16321982)
21. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
22. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
23. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
24. Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro.
Yi W; Shi J; Zhao G; Zhou XE; Suino-Powell K; Melcher K; Xu HE
Sci Rep; 2017 Jan; 7():41487. PubMed ID: 28128331
[TBL] [Abstract][Full Text] [Related]
25. Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms.
Pandhare J; Cooper SK; Phang JM
J Biol Chem; 2006 Jan; 281(4):2044-52. PubMed ID: 16303758
[TBL] [Abstract][Full Text] [Related]
26. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
Jang JY; Bae H; Lee YJ; Choi YI; Kim HJ; Park SB; Suh SW; Kim SW; Han BW
Sci Rep; 2018 Jan; 8(1):31. PubMed ID: 29311579
[TBL] [Abstract][Full Text] [Related]
27. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
28. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
Gurnell M; Wentworth JM; Agostini M; Adams M; Collingwood TN; Provenzano C; Browne PO; Rajanayagam O; Burris TP; Schwabe JW; Lazar MA; Chatterjee VK
J Biol Chem; 2000 Feb; 275(8):5754-9. PubMed ID: 10681562
[TBL] [Abstract][Full Text] [Related]
29. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
[TBL] [Abstract][Full Text] [Related]
30. Involvement of insulin-like growth factor binding protein-3 in peroxisome proliferator-activated receptor gamma-mediated inhibition of breast cancer cell growth.
Pon CK; Firth SM; Baxter RC
Mol Cell Endocrinol; 2015 Jan; 399():354-61. PubMed ID: 25449421
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.
Armoni M; Kritz N; Harel C; Bar-Yoseph F; Chen H; Quon MJ; Karnieli E
J Biol Chem; 2003 Aug; 278(33):30614-23. PubMed ID: 12777391
[TBL] [Abstract][Full Text] [Related]
32. Peroxisome proliferator-activated receptor γ agonism attenuates endotoxaemia-induced muscle protein loss and lactate accumulation in rats.
Crossland H; Constantin-Teodosiu D; Gardiner SM; Greenhaff PL
Clin Sci (Lond); 2017 Jul; 131(13):1437-1447. PubMed ID: 28536293
[TBL] [Abstract][Full Text] [Related]
33. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
34. PPARγ agonists upregulate sphingosine 1-phosphate (S1P) receptor 1 expression, which in turn reduces S1P-induced [Ca(2+)]i increases in renal mesangial cells.
Koch A; Völzke A; Puff B; Blankenbach K; Meyer Zu Heringdorf D; Huwiler A; Pfeilschifter J
Biochim Biophys Acta; 2013 Nov; 1831(11):1634-43. PubMed ID: 23906789
[TBL] [Abstract][Full Text] [Related]
35. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
Guo YT; Leng XS; Li T; Zhao JM; Lin XH
World J Gastroenterol; 2004 Dec; 10(23):3419-23. PubMed ID: 15526359
[TBL] [Abstract][Full Text] [Related]
37. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
38. A Pharmacogenetic Approach to the Treatment of Patients With
Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
[TBL] [Abstract][Full Text] [Related]
39. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation.
Jang JY; Kim H; Kim HJ; Suh SW; Park SB; Han BW
Sci Rep; 2019 Aug; 9(1):11168. PubMed ID: 31371757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
